. The distribution of de novo SNVs and indels per child closely approximated the Poisson distribution expected for random mutational events (Extended Data Fig. 2 ).
We classified 28% (n 5 317) of children with probable pathogenic variants (Supplementary Table 4 and ref. 13 ) in 1,129 robustly implicated developmental disorder genes (published before November 2013), or with pathogenic deletions or duplications. Most of these diagnoses involved de novo SNVs, indels or CNVs (Table 1) . Females had a significantly higher diagnostic yield of autosomal de novo mutations than males (P 5 0.01, Fisher's exact test). Among the single-gene diagnoses, most genes linked to developmental disorders (95 out of 148) were only observed once, although eight (ARID1B, SATB2, SYNGAP1, ANKRD11, SCN1A, DYRK1A, STXBP1, MED13L) each accounted for 0.5-1% of children in our cohort (Extended Data Fig. 3 ). For seventeen of these children we identified two different genes with pathogenic variants, resulting in a composite clinical phenotype.
Analyses that assess the enrichment in patients of a particular class of variation, so-called 'burden analyses', both highlight classes of variants for detailed analysis and enable estimation of the proportion of a particular class of variant that is likely to be pathogenic. We observed a significant (P 5 0.0004) burden of 87 de novo CNVs in the 1,133 children with developmental disorders compared to 12 in 416 controls (Scottish Family Health Study 14 ) despite most children (77%) having previously had clinical microarray testing (Extended Data Fig. 4) .
We used gene-specific mutation rates that account for gene length and sequence context 15 to assess the burden of different classes of de novo SNVs and indels (Supplementary Information). We observed no significant excess of any functional class of de novo SNVs or indels in autosomal-recessive developmental-disorder-linked genes (Extended Data Fig. 5 ), suggesting that few of these mutations are causally implicated. By contrast, we observed a highly significant excess of all 'functional' classes (coding and splice site variants excepting synonymous changes) of de novo SNVs and indels in the dominant and X-linked developmental-disorder-linked genes (Extended Data Fig. 5 ) within which de novo mutations can be sufficient to cause disease. Not all protein-altering mutations in known dominant and X-linked developmental disorder genes will be pathogenic, and these burden analyses inform estimates of positive predictive values for different classes of mutations. The remaining genes (that is, those not linked to developmental disorder) in the genome also exhibit a more modest, but significant, excess of functional, but not silent, de novo SNVs and indels (Extended Data Fig. 5 ).
We observed 96 genes with recurrent, functional mutations (Fig. 1a) , a highly significant excess compared to the expected number derived from simulations (median 5 55; Supplementary Information). This enrichment is even more pronounced (observed, 29; expected, 3) for recurrent loss-of-function mutations (Fig. 1b) . Among undiagnosed children, we observed an excess of 22 genes (observed: 45, expected: 23) with recurrent functional mutations (Fig. 1a ) and an excess of 8 genes (observed, 9; expected, 1) with recurrent loss-of-function mutations (Fig. 1b) , implying that an appreciable fraction of these recurrently mutated genes are novel developmental-disorder-linked genes.
To identify individual genes enriched for damaging de novo mutations (Supplementary Information), we tested for a gene-specific overabundance of either de novo loss-of-function mutations or clustered functional de novo mutations in 1,130 children (excluding one twin from each of three identical twin pairs). To increase power to detect genes associated with developmental disorder, we also meta-analysed our data with published de novo mutations from 2,347 developmental disorder trios with intellectual disability 4, 9 , epileptic encephalopathy 3 , autism [6] [7] [8] 10 , schizophrenia 5 , or congenital heart defects 11 (the 'meta-DD' data set). These analyses (Fig. 2) successfully re-discovered 20 known genes linked to developmental disorder at genome-wide significance (P , 1.31 3 10
26
, a Bonferroni P value of 0.05 corrected for 38,504 tests (Supplementary Information)). Thus, despite the broad phenotypic ascertainment in these data sets, we can robustly detect developmentaldisorder-linked genes solely on statistical grounds.
To increase our power to detect novel genes linked to developmental disorder, we repeated the gene-specific analysis described above excluding the 317 individuals with a known cause of their developmental disorder. In this analysis the statistical genetic evidence was integrated with phenotypic similarity of patients, available data on model organisms and functional plausibility. We identified twelve novel disease genes with compelling evidence for pathogenicity (Table 2) , nine of which exceeded the genome-wide significance threshold of 1.36 3 10 26 (Supplementary Information), with the remaining three genes (PCGF2, DNM1 and TRIO) just below this significance threshold. The two children with identical Pro65Leu mutations in PCGF2, which encodes a component of a Polycomb transcriptional repressor complex, share a strikingly similar facial appearance representing a novel and distinct dysmorphic syndrome. DNM1 was previously identified as a candidate gene for epileptic encephalopathy 3 . Two of the three children that we identified with DNM1 mutations also had seizures, and a heterozygous mouse mutant manifests seizures 16 . In addition to two de novo missense SNVs in TRIO, we identified an intragenic de novo 82-kilobase (kb) deletion of 16 exons. For several of these novel developmentaldisorder-linked genes, the meta-DD analysis increased the significance of enrichment. For example, a total of five de novo loss-of-function variants in POGZ were identified, two from our cohort, two from recent autism studies 6, 7 and one from a recent schizophrenia study 5 . We also identified six genes with suggestive statistical evidence of being novel genes associated with developmental disorder, defined as having a P value for mutation enrichment less than 1 3 10 24 and being plausible from a functional perspective (Extended Data Table 1 ). We anticipate that most of these genes will eventually accrue sufficient evidence to meet the stringent criteria we defined above for declaring a novel developmental-disorder-linked gene.
Notably, we observed identical missense mutations in unrelated, phenotypically similar patients for four of these novel developmentaldisorder-linked genes (PCGF2, COL4A3BP, PPP2R1A and PPP2R5D), and for a fifth gene, BCL11A, we identified highly significant clustering of non-identical missense mutations (Fig. 3) . We hypothesize that the mutations in some of these genes may be operating by either dominantnegative or activating mechanisms. This hypothesis is supported by previous functional evidence for several of the mutated amino acids. The three identical Ser132Leu mutations in COL4A3BP, which encodes an intracellular transporter of ceramide, remove a serine that when phosphorylated downregulates transporter activity from the ER to the The -log 10 (P) value of testing for mutation enrichment is plotted only for each gene with at least one mutation in DDD children. On the x axis is the P value of the most significant test in the DDD data set; on the y axis is the minimal P value from the significance testing in the meta-analysis data set. Red indicates genes already known to be associated with developmental disorders (in DDG2P). Only genes with a P value of less than 0.05/18,272 (red lines) (where 18,272 is the number of genes tested) are labelled. 17 , presumably resulting in intra-cellular imbalances in ceramide and its downstream metabolic pathways. The two mutated amino acids (Arg182Trp and Pro179Leu) in PPP2R1A, which encodes the scaffolding A subunit of the protein phosphatase 2 complex, have been previously identified as sites of driver mutations in endometrial and ovarian cancer 18 . It has previously been shown that mutating either of these two residues results in impaired binding of B subunits of the complex 18 . Intriguingly, PPP2R5D encodes one of the possible B subunits of the same protein phosphatase 2 complex, suggesting that the clustered missense mutations (Pro201Arg and Glu198Lys) in this gene may similarly perturb interactions between subunits of this complex. Further functional studies will be required to confirm this hypothesis.
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We assessed transmission biases of potentially pathogenic inherited SNVs in our probands (Supplementary Information) and observed a genome-wide trend (P 5 0.015) towards over-transmission to probands of very rare (minor allele frequency (MAF) ,0.0005%) loss-of-function variants, but not damaging missense variants. We also observed a 1.8-fold enrichment (P 5 0.04) of rare (MAF ,5%) biallelic loss-of-function variants (Supplementary Table 5 ) among probands without a likely dominant cause of their disorder, compared to those with either a diagnostic de novo mutation or an affected parent. Again we saw no enrichment in biallelic damaging missense variants (Extended Data Table 2), consistent with a similar observation in children with autism 19 . These observations suggest that although inherited loss-of-function variants (both monoallelic and biallelic) are probably contributing to developmental disorder in our patients, much larger sample sizes will be required to pinpoint specific developmental-disorder-linked genes in this way.
To direct future, detailed functional experiments on the developmental role of a subset of candidate genes from this study we used two approaches. First, knockdown-induced phenotypes were recorded in early zebrafish development. Second, we performed a systematic review of perturbed gene function in human, mouse, Xenopus, zebrafish and Drosophila. In both approaches the animal phenotypes were compared to those seen in individuals in our cohort.
We undertook an antisense-based loss-of-function screen in zebrafish to assess 32 candidate developmental-disorder-linked genes with de novo loss-of-function, de novo missense or biallelic loss-of-function variants from exome sequencing (Supplementary Information and Supplementary Table 6 ). These candidate genes corresponded to 39 zebrafish orthologues. Knockdowns of these zebrafish genes were repeated at least twice and all morpholinos were co-injected with tp53 morpholino to eliminate off-target toxicity. Successful knockdown of the targeted messenger RNA could be confirmed using polymerase chain reaction with reverse transcription (RT-PCR) for 82.4% of genes (28 out of 34), and 9 out of 11 (82%) of genes that were tested gave an equivalent phenotype when knocked down by a second, independent morpholino. Knockdown of at least one or a pair of zebrafish orthologues of 65.6% of candidate developmental-disorder-linked genes (21 out of 32) resulted in perturbed embryonic and larval development (Fig. 4 , Extended Data Table 3 , Supplementary Data and Supplementary Table 7) . Large-scale mutagenesis 20 and morpholino 21 studies suggest that knockout or knockdown of 6-12% of genes give developmental phenotypes, suggesting at least a fivefold enrichment of developmentally non-redundant genes among the 32 selected for modelling. We then compared the phenotypes of the zebrafish morphants to those of the patients with de novo mutations or biallelic loss-of-function variants in the orthologous genes (Extended Data Table 3 ). Eleven out of twenty-one (52.4%) of the genes were categorized as strong candidates based on phenotypic similarity (Fig. 4a) . Seven out of eleven were potential microcephaly genes, the knockdown of which in zebrafish gives significant reductions in both head measurements and neural tissue (Fig. 4b and Supplementary Information). Six out of twenty-one (28.6%) genes resulted in severe morphant The table summarizes the 12 genes with compelling evidence to be novel developmental-disorder-linked genes. The number of unrelated patients with independent functional or loss-of-function (LOF) mutations in the Deciphering Developmental Disorders (DDD) cohort or the wider meta-analysis (meta) data set including DDD patients is listed. The P value reported is the minimum P value from the testing of the DDD data set and the meta-analysis data set. The data set that gave this minimal P value is also reported. Mutations are considered to be clustered if the P value of clustering of functional SNVs is less than 0.01. Predicted haploinsufficiency is reported as a percentile of all genes in the genome, with ,0% being highly likely to be haploinsufficient and 100% very unlikely to be haploinsufficient, based on the prediction score described in ref. 
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phenotypes which could not be meaningfully linked to patient phenotypes. As many of our candidate developmental disorder genes carried heterozygous loss-of-function variants (de novo mutations), it is to be expected that the severity of loss-of-function phenotypes in zebrafish may exceed that observed in our patient cohort. The genes with proven non-redundant developmental roles can reasonably be assigned higher priority for downstream functional investigations and genetic analyses.
Our systematic review of gene perturbation in multiple species sought both confirmatory and contradictory (for example, healthy homozygous knockout) evidence from other animal models for these 21 apparently developmentally important genes. We identified 16 genes with solely confirmatory data, often from multiple different organisms, none with solely contradictory data, two with both confirmatory and contradictory evidence, and three with no evidence either way (Supplementary Table 8 ).
In summary, our analyses validate a large-scale, genotype-driven strategy for novel developmental-disorder-linked gene discovery that is complementary to the traditional phenotype-driven strategy of studying patients with very similar presentations, and is particularly effective for discovering novel developmental disorders with highly variable or indistinct clinical presentations. Our meta-analysis with previously published developmental disorder studies increased power to detect novel developmental-disorder-linked genes and highlights the shared genetic aetiologies between diverse neurodevelopmental disorders such as intellectual disability, epilepsy, autism and schizophrenia 22 . We identified significantly more pathogenic autosomal de novo mutations in females compared to males. An increased burden of monogenic disease among females with neurodevelopmental disorders has become more apparent 23, 24 , and our observations strengthen this proposition. Further investigations are required to assess whether males might be enriched for poly/oligogenic causation.
The 35 patients with pathogenic mutations in the 12 novel developmental-disorder-linked genes we discovered increased our diagnostic yield from 28% to 31%. This raises the question of what are the causes of the developmental disorders in the other 69% of patients. The undiagnosed patients are not obviously less severely affected than the diagnosed patients (for example, fewer phenotype terms, older age of recruitment). We anticipate that there are many more pathogenic, monogenic, coding mutations in these undiagnosed patients that we have detected, but for which compelling evidence is currently lacking. This hypothesis is supported by four strands of evidence: (1) modelling statistical power suggests that studying ,1,000 trios has only 5-10% power to detect an averagely mutable haploinsufficient developmental-disorder-linked gene (Extended Data Fig. 6a and Supplementary Information); (2) the expectation that our power to detect novel developmental-disorder-linked genes that operate recessively or by gain-of-function mechanisms will be lower than for haplosufficient genes; (3) the significant enrichment in undiagnosed patients of functional mutations in genes predicted to exhibit haploinsufficiency (Extended Data Fig. 6b) ; and (4) the strong enrichment for developmental phenotypes in the zebrafish knockdown screen.
Given our limited power to detect pathogenic mutations that act through dominant-negative or activating mechanisms, it was notable that in four of our novel genes (COL4A3BP, PPP2R1A, PPP2R5D and PCGF2) we observed identical de novo mutations in unrelated trios. Two hypotheses might explain this observation. First, that there is a vast number of different gain-of-function mutations, of which we are just scratching the surface in this study, or second, that these particular variants are enriched in our cohort owing to these mutations conferring a positive selective advantage in the germ line 25 . Analysis of larger data sets will be required to assess these hypotheses, although they are not necessarily mutually exclusive.
These considerations of the limited power of even nationwide studies such as ours motivate the international sharing of minimal genotypic and phenotypic data, for example through the DECIPHER web portal (http://decipher.sanger.ac.uk), to provide diagnoses for patients who would otherwise remain undiagnosed. Plausibly pathogenic variants observed in undiagnosed patients in our study (de novo SNVs, indels and CNVs, and biallelic loss of function in genes not yet associated with disease) are shared through DECIPHER, and we encourage other, comparable studies to adopt a similar approach.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. RESEARCH LETTER
